No Data
No Data
Sihuan Pharmaceutical Narrows 2023 Loss on Absence of Asset, Investment Impairments
Sihuan Pharmaceutical (HKG:0460) narrowed its 2023 loss attributable to owners to 54.0 million yuan, or 0.0058 yuan per share, from 1.91 billion yuan, from 0.2090 yuan per share, the previous year. Th
The Three-year Earnings Decline Has Likely Contributed ToSihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders Losses of 69% Over That Period
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been particularly tough on longer term Sihuan Pharmaceutical Holdings Group Ltd. (HK
Sihuan Pharmaceutical (00460) announced its 2023 annual results, with total revenue reaching 1,860.5 billion yuan. The revenue of the medical and aesthetic division increased by about 200.3% year-on-year
According to Zhitong Finance App News, Sihuan Pharmaceutical (00460) released its annual results for the year ended December 31, 2023, with total revenue of approximately RMB 1,8605 million; of these, revenue from medical and aesthetic products was RMB 449.9 billion, up about 200.3% year on year, mainly due to the full liberalization of domestic epidemic control and the gradual recovery of consumer demand, the Group's medical and aesthetic platform Qianyan Space achieved phased success through channel inventory cleaning, strategic cooperation with many medical and aesthetic institutions, and vigorously promoted the 3.0 version upgrade of the marketing strategy. Successfully achieved medical and aesthetic sales revenue
SIHUAN PHARM: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Sihuan Pharmaceutical's RF Device Wins Registration Approval in China
Sihuan Pharmaceutical Holdings (HKG:0460) received a class III medical device registration certificate for Sylfirm X from the National Medical Products Administration of China, according to a filing w
Sylfirm X, a dual-wave radiofrequency therapy device exclusively represented by Sihuan Pharmaceutical (00460.HK), was issued a registration certificate for three types of medical devices by the State Drug Administration
GLONGHUI March 25 丨 Sihuan Pharmaceutical (00460.HK) announced that it is the exclusive agent of the Group and is managed by Korea's Vio Co., Ltd. (Viol.co. , Ltd.) The dual-wave radiofrequency therapy device Sylfirm X (the “Product”) manufactured by (“Vio Korea”) officially obtained a Class III medical device registration certificate issued by China's State Drug Administration on March 19, 2024. Sylfirm X is the world's first dual-wave radiofrequency treatment device approved by the US Food and Drug Administration (FDA) and the National Drug Administration. It emits high-frequency electric current to promote skin tissue coagulation, which can effectively reduce skin wrinkles
No Data
102326032 : Pro
投智者KTOP 102326032: Haiz... Cham..
102326032 : Too chim, don’t understand haha
102326032 : So you own this stocks?
投智者KTOP 102326032: Ya.. I expect it up.
View more comments...